Cingulate Inc. (CING)
NASDAQ: CING · Real-Time Price · USD
4.760
-0.220 (-4.42%)
Jan 17, 2025, 4:00 PM EST - Market closed
Cingulate Employees
Cingulate had 13 employees as of December 31, 2023. The number of employees decreased by 2 or -13.33% compared to the previous year.
Employees
13
Change (1Y)
-2
Growth (1Y)
-13.33%
Revenue / Employee
n/a
Profits / Employee
-$1,257,573
Market Cap
15.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 13 | -2 | -13.33% |
| Dec 31, 2022 | 15 | -1 | -6.25% |
| Dec 31, 2021 | 16 | 4 | 33.33% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novartis AG | 76,057 |
| Merck & Co. | 72,000 |
| Novo Nordisk | 64,319 |
CING News
- 4 weeks ago - Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000 - GlobeNewsWire
- 2 months ago - Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market - GlobeNewsWire
- 3 months ago - Cingulate's Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show - GlobeNewsWire
- 4 months ago - Cingulate Initiates Final Study for Lead ADHD Asset CTx-1301 - GlobeNewsWire
- 5 months ago - Cingulate to Participate in Benzinga All Live Access Event - GlobeNewsWire
- 5 months ago - Cingulate Announces Adjournment of Special Meeting - GlobeNewsWire
- 5 months ago - Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy? - Invezz
- 5 months ago - Cingulate Issued European Patent for Lead Asset CTx-1301 for the Treatment of ADHD - GlobeNewsWire